EPHA2 and breast cancer: A study found the immunosuppressive drug leflunomide inhibited angiogenesis in bladder carcinogenesis model via significant inhibition of the sEphrin‐A1/EphA2 system and might be a potential biomarker for treating BC beyond immunosuppressive therapy.24